Pancreatic Cancer Research

Clinical trialPhase 1Withdrawn

Selective Transvenous Chemoembolization of Primary Pancreatic Tumors

Outcome
Stopped earlyWe need to make significant adjustments to proposed drug and its delivery method (Other)
Phase
Phase 1
Status
Withdrawn
Study type
Interventional
Planned start
July 2019
Planned end
December 2021
Enrollment
0 participants
Sites
1
Primary outcomes
Feasibility as determined by technical success of Pancreatic Retrograde Venous Infusion (PRVI) with gemcitabine and Lipiodol®; Safety as measured by number of participants with Grade 3, 4, and 5 toxicities
Sponsor type
Academic / other
Results posted
No
Last update
27 January 2020

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

Catheter directed retrograde venous infusion of gemcitabine/lipiodol into pancreatic tumors.

Detailed description public domain (ClinicalTrials.gov)

Overall, subjects with resectable, borderline-resectable and/or locally-advanced pancreatic cancer are eligible to be entered into the study. Each enrolled study subject will receive a single neoadjuvant pancreatic retrograde venous infusion (PRVI) administration of the gemcitabine/Lipiodol® emulsion. Complete enrollment in 12 months from date of enrollment of first study subject.